With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People's Liberation Army General Hospital shared insights on the committee members' demeanor, the crucial role of young doctors within the association, and experiences and advice for young doctors on their growth path. Drawing from his own experiences, Professor Jiang encouraged young doctors to seize opportunities, actively engage in clinical practice and research, and contribute to both personal and societal value. He also offered words of encouragement to students aspiring to enter the medical field, urging them to pursue their dreams and contribute to the advancement of medical science in China.

The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a study analyzed the efficacy of different immunotherapy combinations for mCRPC patients and examined potential biomarkers.

In the second part of their discussion at ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) examined the evolving…

At ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) discussed VHL-associated renal cell carcinoma (RCC) and the latest Belzutifan data.…

European Hematology Association (EHA) 2024 Wrap-Up: A Confluence of Innovation and Collaboration The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology

Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year's study analyzed data from advanced UC patients in the United States. This article summarizes and organizes the findings for our readers.